NASDAQ$IMVT
Immunovant Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close · Investor relations
Briefing
Reported financial results for the fourth quarter and fiscal year ended March 31, 2025
Immunovant reported a net loss of $106.4 million for the fourth quarter of fiscal year 2025, an increase from the $75.3 million net loss in the same period last year. This was primarily driven by increased research and development and general and administrative expenses.
- Immunovant reported a net loss of $106.4 million for Q4 2025, compared to $75.3 million for Q4 2024.
- Research and development expenses increased to $93.7 million in Q4 2025 from $66.1 million in Q4 2024.
- General and administrative expenses rose to $20.2 million in Q4 2025 from $14.8 million in Q4 2024.
- As of March 31, 2025, cash and cash equivalents were approximately $714 million.
Headline financials
Revenue & EPS history
Immunovant · Revenue · Quarterly
$0
Forward guidance
Immunovant is focused on advancing its clinical programs, including initiating potentially registrational trials for IMVT-1402 in Sjögren’s disease and a second trial in Graves’ disease in summer 2025. The company expects data readouts from other trials in the second half of 2025 and 2027.
Tailwinds
- Initiating potentially registrational trials for IMVT-1402 in Sjögren’s disease and a second trial in Graves’ disease in summer 2025.
- Positive data reported from batoclimab trials in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP).
- Potentially registrational trials for IMVT-1402 in MG and CIDP are actively enrolling.
- Initiated a potentially registrational trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) and a proof-of-concept study in cutaneous lupus erythematosus (CLE) in March 2025.
- Current cash balance provides runway for announced indications through GD readout expected in 2027.
Headwinds
- No specific negative forward guidance points were provided in the report.
- Clinical trial results may not be predictive of final outcomes.
- Timing and availability of data from clinical trials may vary.
- Regulatory approvals may not be received within expected timelines or at all.
- Product candidates may not be beneficial to patients or successfully commercialized.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2025
+0.6%
Avg return
Earnings day
-1.7%
Avg return
5 days after
+2.2%
Avg return
30 days after
54%
15 / 28 earnings
Positive
+35.1%
Q4 2027
Best reaction
-34.6%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2027 | +35.1% | — | — | |
| Q3 2026 | +12.4% | +7.8% | +10.8% | |
| Q2 2026 | +0.0% | +1.7% | +0.9% | |
| Q1 2026 | -4.5% | -1.6% | +4.8% | |
| Q4 2025 | -0.2% | +3.0% | +8.1% | |
| Q3 2025 | -9.6% | -14.1% | -11.1% | |
| Q2 2025 | -2.5% | -6.8% | -8.9% | |
| Q1 2025 | +1.0% | +9.4% | +25.9% | |
| Q4 2024 | -7.1% | -11.3% | -7.1% | |
| Q3 2024 | +4.0% | +4.6% | -10.4% | |
| Q2 2024 | -2.3% | +4.7% | +17.4% | |
| Q1 2024 | +7.4% | -1.9% | +11.5% | |
| Q4 2023 | +4.9% | -0.8% | -5.1% | |
| Q3 2023 | +0.7% | +2.0% | -6.9% | |
| Q2 2023 | +6.3% | -2.1% | +23.2% | |
| Q1 2023 | +19.4% | +24.7% | +23.7% | |
| Q4 2022 | -12.6% | -20.4% | +0.2% | |
| Q3 2022 | -2.7% | -2.5% | -8.8% | |
| Q2 2022 | +1.1% | -0.3% | -12.8% | |
| Q1 2022 | +4.4% | +1.7% | +15.5% | |
| Q4 2021 | -34.6% | -34.5% | -25.0% | |
| Q3 2021 | -13.6% | -18.6% | -25.0% | |
| Q2 2021 | +3.1% | +7.3% | -4.0% | |
| Q1 2021 | +3.7% | +2.3% | +40.2% | |
| Q4 2020 | -11.0% | -13.5% | -14.2% | |
| Q3 2020 | +12.5% | +13.2% | +1.3% | |
| Q2 2020 | +0.1% | +0.1% | +13.9% | |
| Q1 2020 | +0.0% | +0.0% | +0.6% | |
| Q3 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro